MX2021006552A - Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. - Google Patents
Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.Info
- Publication number
- MX2021006552A MX2021006552A MX2021006552A MX2021006552A MX2021006552A MX 2021006552 A MX2021006552 A MX 2021006552A MX 2021006552 A MX2021006552 A MX 2021006552A MX 2021006552 A MX2021006552 A MX 2021006552A MX 2021006552 A MX2021006552 A MX 2021006552A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- adrenal hyperplasia
- congenital adrenal
- pharmaceutical formulations
- solid forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/52—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Se proporcionan métodos para tratar hiperplasia suprarrenal congénita en un sujeto en necesidad del mismo que comprende administrar 4-(2-cloro-4-metoxi-5-metilfenil)-N-[(1S)-2-ciclopropi l-1-(3-fluoro-4-metilfenil)etil]-5- metil-N-prop-2-inil-1,3-tiazol -2-amina (fórmula 1) o una sal farmacéuticamente aceptable de la misma. Se proporcionan además formulaciones farmacéuticas y formas sólidas de 4-(2-cloro-4-metoxi-5-metilfenil)-N-[(1S)-2-cicl opropil-1-(3-fluoro-4-metilfenil)etil]-5-metil-N-prop-2-inil-1,3- tiazol-2-amina o una sal farmacéuticamente aceptable de la misma, y sus usos en el tratamiento de hiperplasia suprarrenal congénita (CAH).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776763P | 2018-12-07 | 2018-12-07 | |
US201962816674P | 2019-03-11 | 2019-03-11 | |
PCT/IB2019/001325 WO2020115555A2 (en) | 2018-12-07 | 2019-12-06 | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006552A true MX2021006552A (es) | 2021-07-07 |
Family
ID=69500780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006552A MX2021006552A (es) | 2018-12-07 | 2019-12-06 | Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. |
MX2022015551A MX2022015551A (es) | 2018-12-07 | 2021-06-09 | Metodos de sintesis para la preparacion de 4-(2-cloro-4-metoxi-5-m etilfenil)-n-[(1s)-2-ciclopropil-1-(3-fluoro-4-metilfenil)etil]-5 -metil-n-prop-2-inil-1,3-tiazol-2-amina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015551A MX2022015551A (es) | 2018-12-07 | 2021-06-09 | Metodos de sintesis para la preparacion de 4-(2-cloro-4-metoxi-5-m etilfenil)-n-[(1s)-2-ciclopropil-1-(3-fluoro-4-metilfenil)etil]-5 -metil-n-prop-2-inil-1,3-tiazol-2-amina. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20220023266A1 (es) |
EP (4) | EP3890706A2 (es) |
JP (4) | JP7238130B2 (es) |
KR (2) | KR20210100669A (es) |
CN (3) | CN113518616A (es) |
AU (2) | AU2019393256A1 (es) |
BR (1) | BR112021010847A2 (es) |
CA (3) | CA3121920A1 (es) |
IL (2) | IL283712A (es) |
MA (2) | MA56226A (es) |
MX (2) | MX2021006552A (es) |
SG (1) | SG11202105930QA (es) |
TW (2) | TW202033193A (es) |
WO (3) | WO2020115555A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ722122A (en) | 2014-01-21 | 2020-06-26 | Neurocrine Biosciences Inc | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
TW202033193A (zh) | 2018-12-07 | 2020-09-16 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
JP2022541550A (ja) * | 2019-07-19 | 2022-09-26 | スプルース バイオサイエンシーズ,インク. | 先天性副腎過形成を処置する方法 |
JOP20220329A1 (ar) * | 2020-06-10 | 2023-01-30 | مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي | |
CN116322544A (zh) | 2020-08-12 | 2023-06-23 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
WO2023049689A1 (en) * | 2021-09-21 | 2023-03-30 | Reveragen Biopharma, Inc. | Treatment of congenital adrenal hypoplasia |
WO2023163945A1 (en) * | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
CN114715871B (zh) * | 2022-04-26 | 2023-09-12 | 四川朗晟新材料科技有限公司 | 一种锂电池用改性磷酸铁锂正极材料及制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754258B1 (fr) * | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
FR2796380B3 (fr) * | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
EP1834641A1 (en) | 2006-03-16 | 2007-09-19 | Sanofi-Aventis | Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia |
HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
EP2841068B8 (en) * | 2012-04-23 | 2019-03-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
NZ722122A (en) | 2014-01-21 | 2020-06-26 | Neurocrine Biosciences Inc | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
WO2016065177A1 (en) * | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
AU2016240213B2 (en) * | 2015-04-02 | 2022-01-27 | HMNC Holding GmbH | Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists |
WO2018219804A1 (en) * | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
TW202033193A (zh) | 2018-12-07 | 2020-09-16 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
-
2019
- 2019-12-06 TW TW108144813A patent/TW202033193A/zh unknown
- 2019-12-06 KR KR1020217020735A patent/KR20210100669A/ko unknown
- 2019-12-06 SG SG11202105930QA patent/SG11202105930QA/en unknown
- 2019-12-06 MX MX2021006552A patent/MX2021006552A/es unknown
- 2019-12-06 EP EP19848938.7A patent/EP3890706A2/en active Pending
- 2019-12-06 WO PCT/IB2019/001325 patent/WO2020115555A2/en active Application Filing
- 2019-12-06 CN CN201980080385.8A patent/CN113518616A/zh active Pending
- 2019-12-06 EP EP21213854.9A patent/EP3984523A1/en active Pending
- 2019-12-06 MA MA056226A patent/MA56226A/fr unknown
- 2019-12-06 US US17/311,310 patent/US20220023266A1/en active Pending
- 2019-12-06 BR BR112021010847-5A patent/BR112021010847A2/pt unknown
- 2019-12-06 JP JP2021531723A patent/JP7238130B2/ja active Active
- 2019-12-06 MA MA054395A patent/MA54395A/fr unknown
- 2019-12-06 AU AU2019393256A patent/AU2019393256A1/en active Pending
- 2019-12-06 CA CA3121920A patent/CA3121920A1/en active Pending
-
2020
- 2020-06-10 WO PCT/IB2020/000575 patent/WO2021111179A1/en unknown
- 2020-06-10 JP JP2022533467A patent/JP2023505232A/ja active Pending
- 2020-06-10 CA CA3160738A patent/CA3160738A1/en active Pending
- 2020-06-10 CN CN202080095702.6A patent/CN115087647A/zh active Pending
- 2020-06-10 US US17/782,617 patent/US20230286932A1/en active Pending
- 2020-06-10 EP EP20753411.6A patent/EP4069682A1/en active Pending
- 2020-12-03 TW TW109142645A patent/TW202136225A/zh unknown
-
2021
- 2021-06-06 IL IL283712A patent/IL283712A/en unknown
- 2021-06-09 WO PCT/IB2021/000403 patent/WO2021250468A2/en active Search and Examination
- 2021-06-09 US US18/009,662 patent/US20230233534A1/en active Pending
- 2021-06-09 JP JP2022575997A patent/JP2023530084A/ja active Pending
- 2021-06-09 CA CA3181126A patent/CA3181126A1/en active Pending
- 2021-06-09 MX MX2022015551A patent/MX2022015551A/es unknown
- 2021-06-09 AU AU2021289538A patent/AU2021289538A1/en active Pending
- 2021-06-09 IL IL298927A patent/IL298927A/en unknown
- 2021-06-09 EP EP21751605.3A patent/EP4164604A2/en active Pending
- 2021-06-09 KR KR1020237000554A patent/KR20230038185A/ko unknown
- 2021-06-09 CN CN202180055872.6A patent/CN116322668A/zh active Pending
-
2023
- 2023-06-09 JP JP2023095439A patent/JP2023105239A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006552A (es) | Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
MX2023001468A (es) | Tratamiento de cancer de prostata. | |
RS54156B1 (en) | COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS | |
PH12017500724A1 (en) | Carbazole derivatives | |
JOP20190191A1 (ar) | وحدات شجرية علاجية | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX2021002556A (es) | Tratamiento del dolor postquirurgico. | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
MX2021006867A (es) | Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmaceuticamente aceptable del mismo. | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
PE20211818A1 (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal | |
CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
AU2018260628A1 (en) | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors |